WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. announced today that its integrated drug discovery collaboration with AstraZeneca has delivered an oral respiratory candidate drug for progression into preclinical development.
Since March 2012, a team of scientists from AstraZeneca and BioFocus, now part of Charles River Discovery Services, worked collaboratively on a respiratory project, with much of the discovery experimental work being conducted at the BioFocus facilities near Cambridge, UK and Leiden, NL. This project has successfully nominated an oral candidate drug for progression into preclinical development. The joint team was also recognised within AstraZeneca Innovative Medicines for its achievements in creatively overcoming a significant safety issue as part of the optimization program.
Help employers find you! Check out all the jobs and post your resume.
